These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34367072)

  • 1. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
    Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
    Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Parghane RV; Talole S; Basu S
    Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
    Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
    Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
    Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
    J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
    Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
    Puranik AD; Kulkarni HR; Singh A; Baum RP
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1223-30. PubMed ID: 25822655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
    Makis W; McCann K; Bryanton M; McEwan AJ
    Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor radionuclide therapy for metastatic paragangliomas.
    Pinato DJ; Black JR; Ramaswami R; Tan TM; Adjogatse D; Sharma R
    Med Oncol; 2016 May; 33(5):47. PubMed ID: 27059363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
    Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
    Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
    Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged response to
    Cottereau AS; Bricaire L; Arrondeau J; Dechmi A; Montravers F; Coriat R; Clerc J; Groussin L; Tenenbaum F
    Invest New Drugs; 2020 Aug; 38(4):1196-1199. PubMed ID: 31650444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.